NewsBenzingaRecursion Announces Sanofi Option Of First Immunology Drug Candidate, Triggering $10M Milestone Payment And Potential Phase 1 Trials In 2027 Recursion Announces Sanofi Option Of First Immunology Drug Candidate, Triggering $10M Milestone Payment And Potential Phase 1 Trials In 2027 Benzinga 2026.10.15 12:42 (GMT+0) Open on Benzinga Other news 'Mentality Issue': PlayStation Founder Waves Away Disc Ownership Anger Bitcoin derivatives market structure shifts: options open interest share rises to nearly 60%, risk management demand grows Tech hedge fund Augnition Global Investors, founded by former Sequoia executive Jeff Wang, completes $1 billion fundraising Tesla-SpaceX Merger Could Hand Musk 58% Voting Control - TipRanks.com OCC Finalizes GENIUS Act Rule, Drops Third-Party Yield Presumption U.S. OCC first to finalize GENIUS Act stablecoin regulation rules, effective January 18, 2027
Bitcoin derivatives market structure shifts: options open interest share rises to nearly 60%, risk management demand grows
Tech hedge fund Augnition Global Investors, founded by former Sequoia executive Jeff Wang, completes $1 billion fundraising
